Science
China now leads the world in trials for next-gen CAR-T therapies
Publication: Nature
Author: Rachel Fieldhouse
Source published: 28/09/2026, 00:00:00 UTC
Briefing created: 29/09/2026, 22:40:08 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 29/09/2026, 10:35:25 UTC.
Briefings
China advanced ahead of global peers in clinical trials for next-generation CAR-T therapies by September 2026, testing faster than other nations. However, regulatory shifts may eventually slow this progress. The study was published in Nature on September 28, 2026, with a DOI available for verification.
Key points
- China conducted clinical trials for next-generation CAR-T therapies significantly faster than other nations by September 2026.
- Regulatory changes in China could slow the progress of these therapies despite the initial speed advantage.
Context and limitations
Evidence covers only China's trials up to September 2026; global comparisons are limited by the source's scope.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 29/09/2026, 22:40:08 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeidhlh3hbrmgeuqzfzfarddhnc7sh7ksoxzgary5ulnreq6dqg2msy